Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autophagy and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TFEB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TFEB Recombinant Protein (Wild-Type & Phospho-mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for DNA-binding and protein-protein interaction assays. |
View TFEB Products |
| Gene Delivery | TFEB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for establishing nuclear translocation and high-content screening assays. |
View TFEB Products |
| Benchmark Ab | Anti-TFEB Recombinant Antibody Recombinant positive control for Western Blot, Immunofluorescence, and ChIP assays. |
View TFEB Products |
| Validator | TFEB siRNA Set For knockdown verification in target specificity validation. |
View TFEB Products |
| Related Target A | TFE3 Homolog in the MiT/TFE family. Critical for off-target and selectivity screening in oncology programs. |
View TFE3 Products |
| Related Target B | MITF Key family member regulating melanogenesis. Counter-screening is vital to avoid pigmentary toxicity. |
View MITF Products |
| Related Target C | mTORC1 Primary upstream kinase phosphorylating TFEB at Ser211, regulating its cytoplasmic retention. |
View mTORC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nuclear Translocation Tracking | Lentivirus Premade Particles expressing GFP-tagged TFEB for real-time high-content imaging. |
| Family Selectivity (TFE3/MITF) | Sequence-verified recombinant protein panels of MiT/TFE family members for cross-reactivity screening. |
| Lack of Controls | High-affinity benchmark antibodies validated for endogenous TFEB detection. |
| False Positives | Target-specific validated siRNA sets included to confirm pathway-dependent downstream gene activation. |
Live TFEB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of TFEB (Transcription Factor EB) is rapidly expanding from its traditional focus on lysosomal storage diseases (LSDs) into neurodegenerative disorders (e.g., Alzheimer's and Parkinson's) and oncology. As the master regulator of autophagy and lysosomal biogenesis, TFEB modulation presents a dual-nature therapeutic profile: activation is desired for clearing toxic protein aggregates in neurodegeneration, whereas inhibition is sought to disrupt lysosomal cytoprotection in resistant cancers.
The race for TFEB therapeutics is intensifying, with major players shifting focus from non-specific upstream kinase inhibitors (like mTOR inhibitors) to direct, selective TFEB small molecule modulators and gene therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting tissue-specific delivery and isoform-selective modulation to minimize systemic toxicities associated with broader MiT/TFE family disruption.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | Biotech startups, Academic Spin-offs | Neurodegeneration (AD, PD), Lysosomal Storage Diseases | Nuclear translocation assays (Need Lentivirus for Stable Cell Lines) |
| Small Molecule Inhibitors | Oncology-focused Biopharma | MiT/TFE-translocation Renal Cell Carcinoma, Pancreatic Cancer | Selectivity assays against MITF/TFE3 (Need Mutant & WT Recombinant Proteins) |
| Gene Therapy (AAV/Lenti) | Gene Therapy Pioneers | Rare Diseases, Severe Neurodegenerative Disorders | Expression validation and target gene knockdown panels (Need siRNA/qPCR primers) |